Mass Spectrometry: Using proteomics to probe neurons

  1. Yunee Kim
  2. Thomas Kislinger  Is a corresponding author
  1. University of Toronto, Canada

Deconstructing the immensely complex molecular basis of neuronal networks in the mammalian brain would help us to better understand how neurons develop and form connections (called synapses) with each other. Significant strides in the analysis of gene expression have been made in recent years, revealing the regulatory programs that govern the fate of individual neurons, their interactions with diverse ligands, and their ability to adapt to changes, such as environmental cues and injuries (Schreiner et al., 2014). However, measures of gene expression might not reflect the actual levels of proteins produced in cells, so efforts are being made to study the proteins directly.

Evidence suggests that changes in the abundance or activity of proteins in synapses may lead to defects in neurons that are implicated in neuropsychiatric disorders (Craft et al., 2013). Therefore, uncovering the repertoire of proteins produced by neurons could help us understand the underlying molecular basis of such conditions. The large-scale study of the proteins found in cells—known as proteomics—poses significant challenges to researchers. For example, a single gene in a mammalian cell can be used as a template to make many different forms (or ‘isoforms’) of a protein through a process called alternative splicing. These isoforms can be very similar to each other, but they can play very different roles in cells, so it is important for proteomics techniques to be able to distinguish them. The situation is further complicated by the presence of large protein families encoded by very similar genes.

Mass spectrometry is the leading approach for proteomics investigations, and encompasses both global analyses of all the proteins found in cells, and ‘targeted’ approaches that accurately measure the abundance of particular proteins. Selected reaction monitoring (SRM) mass spectrometry is the most widely used technique for targeted proteomics (Elschenbroich and Kislinger, 2011). Proteins are extracted from cells and digested by enzymes to produce millions of fragments (called peptides). However, only a small fraction of these peptides will be unique to the protein or isoform of interest. SRM mass spectrometry is able to accurately determine protein abundance because it can be used to measure just those peptides we are interested in.

The absolute quantification of proteins by SRM involves ‘spiking’ the samples with known concentrations of labelled synthetic peptides after the enzyme treatment (Barr et al., 1996). However, variations in the efficiency of the enzymes can lead to errors with this approach. Alternative approaches use known concentrations of labelled whole synthetic proteins (Brun et al., 2007; Stergachis et al., 2011), which are added to the sample before the enzyme treatment.

However, the use of SRM mass spectrometry to quantify the isoforms of protein families from complex tissues had not been explored. Now, in eLife, Peter Scheiffele and colleagues at the University of Basel—including Dietmar Schreiner and Jovan Simicevic as joint first authors—have developed SRM assays to quantify the isoforms of the neurexin family of proteins in the mouse brain (Schreiner, Simicevic et al. 2015).

Neurexins are cell adhesion proteins that play important roles in the formation and differentiation of synapses (Zhang et al., 2010). All three of the genes that encode neurexin proteins contain various segments that can be removed from messenger RNA in different combinations by alternative splicing (Chih et al., 2006). The modified messenger RNA molecules are then translated to make the different neurexin protein isoforms. The segments have been shown to regulate the interactions between ligands and their receptors on the surface of neurons and to alter the activity of synapses in a variety of ways (Aoto et al., 2013).

Schreiner, Simicevic et al. made protein standards that contained different neurexin isoforms fused to the fluorescent protein GFP before carrying out SRM assays (Figure 1). They found that, in several different regions of the brain, neurexin isoforms that contain the segments known as AS3 and AS4 were regulated in the same way, but isoforms that contain another segment called AS6 were regulated independently.

Absolute quantification of proteins by SRM mass spectrometry.

A master mix containing the components required for protein synthesis, the amino acids arginine and lysine labeled with carbon-13 and nitrogen-15, and all other unlabeled amino acids are mixed with cDNA molecules that encode the proteins of interest fused with green fluorescent protein (GFP). These fusion proteins (indicated in green-red) are combined with a sample containing the target proteins of interest (depicted in blue), and a known concentration of unlabeled GFP as an internal standard (shown in yellow). This protein mixture is digested by enzymes and the resulting peptides are analyzed by SRM mass spectrometry that specifically measures peptides that are unique to the target proteins. The resulting SRM traces contain information about the abundance of these peptides. The known spiked concentration of the unlabeled GFP standard (yellow) is used to determine the absolute amounts of the labeled GFP fusion protein standard (the green part of the fusion protein). In turn, the target protein component of the GFP fusion protein standard (the red section) is used to determine the absolute amounts of the target proteins in the biological sample (shown in blue).

The absolute quantification of the neurexins revealed that two of the isoforms (called alpha and beta) differed in abundance and that, overall, neurexins are present at relatively high levels across the whole mouse brain. The ability of neurexin isoforms to interact with ligands at synapses was associated with specific segments, which demonstrates that alternative splicing can modulate neurexin activity.

The SRM assays developed by Schreiner, Simicevic et al. enabled them to discriminate between neurexin isoforms that only differed in a single amino acid residue. Their simple approach can be applied to other protein families in any accessible tissue, and hence may be applied to a range of biological questions.

References

    1. Barr JR
    2. Maggio VL
    3. Patterson DG Jr
    4. Cooper GR
    5. Henderson LO
    6. Turner WE
    7. Smith SJ
    8. Hannon WH
    9. Needham LL
    10. Sampson EJ
    (1996)
    Isotope dilution–mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I
    Clinical Chemistry 42:1676–1682.

Article and author information

Author details

  1. Yunee Kim

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Thomas Kislinger

    Department of Medical Biophysics, University of Toronto, Toronto, Canada
    For correspondence
    thomas.kislinger@utoronto.ca
    Competing interests
    The authors declare that no competing interests exist.

Publication history

  1. Version of Record published:

Copyright

© 2015, Kim and Kislinger

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,389
    views
  • 172
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yunee Kim
  2. Thomas Kislinger
(2015)
Mass Spectrometry: Using proteomics to probe neurons
eLife 4:e09103.
https://doi.org/10.7554/eLife.09103
  1. Further reading

Further reading

    1. Cancer Biology
    2. Cell Biology
    Ida Marie Boisen, Nadia Krarup Knudsen ... Martin Blomberg Jensen
    Research Article

    Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2. Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap, protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap/Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.